Skip to main content
padlock icon - secure page this page is secure

Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Buy Article:

$52.00 + tax (Refund Policy)

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B‐cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: B‐cell depletion; pneumonitis; rituximab; systemic autoimmune disease; systemic lupus erythematosus

Document Type: Research Article

Affiliations: Immunology Department, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

Publication date: April 1, 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more